FDA leadership gap deepens uncertainty for biotech as acting officials take charge

Marty Makary's resignation as FDA commissioner has left the agency without a permanent head. Kyle Diamantas is serving as the temporary leader, while three senior drug-review positions are filled by acting officials.

Each acting official can serve for up to 210 days under federal law, after which a permanent nominee must be confirmed. The limited tenure raises the prospect of further turnover as the White House and HHS Secretary Robert F. Kennedy Jr. look for full-time appointees.

Industry observers worry that the next permanent appointee may either continue the biotech-friendly policies championed by Makary or adopt a more restrictive stance, leaving the sector uncertain about the FDA's future regulatory direction.